Therese Gutter

Therese Gutter

Auto-generated profile, based on publicly available information

Therese Gutter

Department of Clinical Neurophysiology and Sleep Centre SEIN Zwolle, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
TGTherese Gutter
Therese Gutter
PCPetra M.C. Callenbach
Petra M.C. Callenbach
OBOebele F. Brouwer
Oebele F. Brouwer
AWAl W. de Weerd
Al W. de Weerd

1 September 2013 in Epilepsy & Behavior
Verified
Journal Article
Closed access
TGTh. Gutter
Th. Gutter
OBO.F. Brouwer
O.F. Brouwer
AWA.W. de Weerd
A.W. de Weerd

1 October 2012 in Epilepsy & Behavior
Verified
Journal Article
Closed access
PDF file
TGTherese Gutter
Therese Gutter
AWAl W. de Weerd
Al W. de Weerd

1 January 1995 in Neuropsychobiology
Verified
Journal Article
Closed access
AAA.P. Aldenkamp
A.P. Aldenkamp
JOJ. Overweg
J. Overweg
JSJ. Smakman
J. Smakman
ABA.M. Beun
A.M. Beun
LDL. Diepman
L. Diepman
BVB. Vledder
B. Vledder
Sabeluzole, a new benzothiazol derivative, has shown positive effects on memory function in animals and in normal volunteers. The present study reports the results of sabeluzole, in memory-impaired patients with localization-related (partial) epilepsy. A randomized, double-blind placebo-controlled parallel-group design was used. A total of 38 patients entered a prospective baseline. Five patients dropped out from the study, thus 33 patients were randomly assigned to either a 12-weeks treatment with sabeluzole (n = 14) or placebo (n = 19). The treatment phase was preceded by a titration phase of 4 weeks to obtain serum levels of sabeluzole between 50 and 130 ng/ml. In order to maintain blindness, a sham titration was carried out in the placebo group. The number of 'responders', i.e. patients with a > 1 SD improvement on at least three of the memory tests was 9 out of 14 (64.3%) in the sabeluzole group and 7 out of 19 (36.8%) in the placebo group. This suggests a clinically relevant effect of sabeluzole. The analysis of the memory tests showed a statistically significant improvement with sabeluzole on the verbal long-term memory test. This could represent a specific drug effect and is in line with previous results of normal volunteer studies that also found improvement mainly restricted to the area of verbal long-term memory.